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Abstract 
Background: Several methods have been proposed to measure cerebrovascular autoregulation (CA) in traumatic 
brain injury (TBI), but the lack of a gold standard and the absence of prospective clinical data on risks, impact on care 
and outcomes of implementation of CA-guided management lead to uncertainty.
Aim: To formulate statements using a Delphi consensus approach employing a group of expert clinicians, that reflect 
current knowledge of CA, aspects that can be implemented in TBI management and CA research priorities.
Methods: A group of 25 international academic experts with clinical expertise in the management of adult severe 
TBI patients participated in this consensus process. Seventy-seven statements and multiple-choice questions were 
submitted to the group in two online surveys, followed by a face-to-face meeting and a third online survey. Partici-
pants received feedback on average scores and the rationale for resubmission or rephrasing of statements. Consensus 
on a statement was defined as agreement of more than 75% of participants.
Results: Consensus amongst participants was achieved on the importance of CA status in adult severe TBI patho-
physiology, the dynamic non-binary nature of CA impairment, its association with outcome and the inadvisability of 
employing universal and absolute cerebral perfusion pressure targets. Consensus could not be reached on the accu-
racy, reliability and validation of any current CA assessment method. There was also no consensus on how to imple-
ment CA information in clinical management protocols, reflecting insufficient clinical evidence.
Conclusion: The Delphi process resulted in 25 consensus statements addressing the pathophysiology of 
impaired CA, and its impact on cerebral perfusion pressure targets and outcome. A research agenda was proposed 
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In the past decades, identifying preventable and manage-
able causes of secondary brain injury has led to reduced 
morbidity and mortality from severe traumatic brain 
injury (TBI). This concept of secondary insults, and the 
supportive evidence, have been summarized and pro-
moted through multiple publications of guidelines and 
algorithms [1–4]. Low cerebral perfusion pressure (CPP) 
has been identified as an important secondary insult, 
though the literature has failed to identify clear targets of 
safe CPP [1, 5, 6].
Cerebrovascular autoregulation (CA) is classically 
defined as the maintenance of cerebral blood flow (CBF) 
over a wide range of CPP. Impairment of CA has long 
been considered a possible contributor to secondary 
injury [7–13]. Several methods to assess CA have been 
proposed and tested in clinical research, but a consen-
sus on their accuracy, reliability and clinical utility is 
still lacking. These methods are based on the effect of 
induced alterations or spontaneous fluctuations of arte-
rial blood pressure (ABP) on surrogate measures for CBF 
(e.g., intracranial pressure (ICP), the pressure–volume 
index; transcranial Doppler (TCD) flow velocities) or 
on direct CBF measurements (e.g., cortical laser Dop-
pler flow (LDF) or perfusion imaging). The relationship 
of these variables with ABP or CPP is either plotted in a 
steady state relationship (static assessment) or by meas-
uring the response over time (dynamic assessment) [10, 
14–19]. Moving correlation coefficients between time-
averaged mean TCD flow velocity and CPP (Mx) and 
between time-averaged mean ICP and ABP (PRx) based 
on waveform quality signals have been introduced, and 
correlations between these metrics and clinical outcomes 
in TBI patients were found [16, 17]. Other proposed indi-
ces correlate another variable indirectly reflecting CBF 
with CPP or ABP in a frequency domain that includes 
slow wave ABP variations. All these metrics correlate 
with each other and with outcome [20]. Further, compu-
tational algorithms have been developed based on PRx 
that enable to identify CPP zones where there is presum-
ably intact or more efficient CA (optimal CPP or CPPopt) 
[21, 22].
Still, the incorporation of monitoring information 
on the status of CA in the management of severe TBI 
remains controversial. While it appears that under cir-
cumstances of raised ICP and intact CA, increasing CPP 
may result in reduced ICP [23], the benefit of computa-
tional calculation of dynamic CPPopt targets based on 
a linear mathematical interpretation of CA has yet to 
be demonstrated in prospective trials [24]. In addition, 
whether CA may be considered a physical quantity with 
a simply measurable metric is questionable. CBF regu-
lation encompasses a complex and vast field of physi-
ological processes, in which pressure-driven changes in 
vascular tone represent just one nonlinear element [25]. 
As well, regulatory mechanisms seem to be heterogene-
ous across the vascular tree and across brain regions [26]. 
At present, no single method can be regarded as the gold 
standard measure of CA.
The inherent validation deficit associated with clini-
cal CA research versus the abundance of computational 
metrics that are appearing in literature with amazing 
regularity, the conceptual difference between steering 
CPP into its plateau region based on CPPopt algorithms 
versus the use of CA information for reducing raised ICP, 
and the absence of results from well-designed prospec-
tive clinical studies versus the referral to CA in guidelines 
[1, 3, 4], leave the neuro-intensive care community in a 
state of uncertainty. Due to all these open questions, even 
experts in neuro-intensive care are divided on the extent 
to which CA information can be implemented in clinical 
practice based on current knowledge.
Therefore, the aim of the current Delphi study was to 
develop consensus amongst expert clinicians on CA 
monitoring and its use in clinical practice. The eventual 
goal is to create clarity based on common opinions and to 
arrive at a common research agenda in order to facilitate 
progress in this promising field.
Methods
A Delphi-method-based approach [27] was adopted to 
obtain consensus of the collective opinions of a group of 
experts. The panel was composed based on the follow-
ing criteria: (1) current and active bedside clinical exper-
tise as a physician in the acute care for adult severe TBI 
patients, (2) active research and/or recent publications in 
this field and academic appointment, (3) sufficient rep-
resentation of the involved disciplines of neurosurgery, 
neurocritical care and neuroanesthesiology, (4) will-
ingness, availability and ability to commit to the Delphi 
study on CA. The final group consisted of 25 experts, of 
whom 17 were neurointensivist/neuroanesthetists and 
emphasizing the need for better validated CA assessment methods as well as the focused investigation of the appli-
cation of CA-guided management in clinical care using prospective safety, feasibility and efficacy studies.
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8 were neurosurgeons. In the Spring of 2019, a commit-
tee of 4 experts (GC, BD, GM, MS) carefully prepared 
a set of 65 statements and 12 multiple choice questions 
(MCQ) on CA and its potential role in the management 
of sedated, ventilated and ICP-monitored adults with 
severe TBI in the intensive care unit. The questionnaire 
was organized into six sections: (1) definition of CA to 
be used in the current Delphi consensus study (i.e., scope 
of the study), (2) impact of CA status on ABP and CPP 
management, (3) CA-based management protocols, (4) 
measurement of CA, (5) association of CA status with 
outcome and (6) recommended CA research agenda. 
Where applicable, participants could add comments 
in relation to the MCQ or statement in a free text box. 
The following methods to measure CA were subjected to 
review by the experts: Autoregulation Index (ARI) [28]; 
Transfer function analysis methods based on TCD flow 
velocity [29]; ICP response to ABP manipulation [3, 4]; 
PRx [17]; L-PRx [30]; LAx [31]; Mx [16]; ORx [32]; Lx 
[33]; TOx [34]; THx [34]; correlation of extracellular 
glutamate measured with microdialysis and CPP [35]; 
and CBFx [36]. Explanatory definitions on the methods 
are included in Supplementary Table 1. The full original 
questionnaire is available as Supplementary Text 1. The 
questionnaire was submitted to the experts via a web 
based survey (SurveyMonkey Inc., San Mateo, California, 
USA, www.surve ymonk ey.com). Experts were requested 
to score agreement with statements by means of a Likert 
scale from 1 to 8 and to answer the MCQ. Consensus was 
defined as >75% agreement. MCQ answers with >75% 
agreement and statements with >75% rating of the three 
lowest or three highest Likert scores were resubmitted to 
the experts in a second round, with the option to agree 
or to disagree (to confirm consensus). MCQ answers 
with >50% and ≤75% agreement and statements with 
>50% and ≤75% rating of the three lowest or three high-
est Likert scores were resubmitted without change along 
with average and personal scores (i.e., each participant 
could compare his individual scores with the averages of 
the group in order to stimulate agreement). If there was 
≤50% agreement, the statement or MCQ was considered 
as resulting in no consensus. After two rounds, a meeting 
was organized at the 17th International Conference on 
Intracranial Pressure and Neuromonitoring in Leuven, 
Belgium on September 8 2019. At the meeting, all results 
were discussed. The group did not have the authority to 
change any of the results of round one and two, but did 
have the authority to rephrase statements when deemed 
appropriate, or to make a proposal regarding the rel-
evance of emphasizing the lack of consensus on a par-
ticular statement. The responses in the comment boxes 
were also discussed. Rephrased statements and proposals 
were submitted to the expert group in a third and final 
web-based survey round. Statements and proposals scor-
ing >75% agreement in round three were retained and are 
presented in the results section.
Results
In round one, >75% agreement was reached in 12/77 
MCQ and statements, and more than 50% and ≤75% 
agreement was found in 30/77 MCQ and statements. In 
round two, >75% agreement was reached in 19/42 MCQ 
and statements (consensus gain of +7), and agreement 
>50% and ≤75% was found in 16/42 MCQ and state-
ments. At the face-to-face discussion in the consensus 
meeting, consensus was confirmed for 19 of round 2 
consensus statements, and there was a decision to subtly 
rephrase 3 without need for new votes. More substantial 
rephrasing was proposed for 4 statements that had not 
previously reached consensus, of which one was split 
into two statements, and one new statement was added 
(see Supplementary Table 2 for rephrased statements and 
their rationale). In 5 instances, it was agreed to make an 
explicit statement that no consensus was reached. Also, 
20 explanatory texts were proposed. All proposals were 
re-submitted to the experts in round three. Consensus 
was obtained for the four rephrased statements (of which 
one was split in two) and for the new statement, bringing 
the total number of consensus statements to 25 (consen-
sus gain of + 6). There was also >75% agreement on the 
five proposals for making a no-consensus statement, and 
all explanatory texts were accepted. The full overview of 
25 consensus statements, five no-consensus statements 
and accompanying explanatory texts in the order of the 
original sections can be found in Supplementary Text 2.
Table  1 summarizes all consensus statements with 
their scores in the different rounds, and Table  2 con-
tains the no-consensus statements. Consensus was high 
on the subjects of Section  1 (scope), 2 (CPP limits), 5 
(associations with outcome) and 6 (research agenda). 
The consensus statements in Sect.  1 reflect that the 
phenomenon of CA was considered from a clinical and 
practical perspective, rather than attempting to define 
its mechanisms. It is important to picture CA impair-
ment as a potentially continuously changing process 
of narrowing of the CPP plateau where CBF remains 
stable, as well as shifting of this plateau on the CPP 
axis. Section  2 describes the impact of CA status on 
CPP management. As a result of the dynamic nature 
of the CBF plateau in the context of TBI and individ-
ual patient characteristics, it is impossible to define 
universal CPP targets that would be safe in all patients 
at all times. The range of the CPP target is inherently 
variable, but nevertheless it has boundaries that are not 
considered safe to violate. All experts agreed that CPP 
should not fall below 50 mmHg (although the real time 
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lower boundary may lie higher). At the same time, the 
experts agreed that at the other extreme, high CPP is 
likely to be harmful too, though there are insufficient 
data available to define an absolute upper boundary. 
As for high CPP, it was argued that pharmacological 
measures to lower CPP (by other means than increas-
ing sedatives) are controversial. The latest version 
of the Brain Trauma Foundation guidelines refers to 
Table 1 Statements on which consensus was reached (R1,2,3 = round 1,2,3)
CA cerebrovascular autoregulation; CBF cerebral blood flow; CPP cerebral perfusion pressure; CPPopt optimal cerebral perfusion pressure; ICP intracranial pressure; 
Pb02 partial pressure of oxygen in the brain tissue; R1,2,3 round 1,2,3
No (section) Consensus statement Score R1 Score R2 Score R3
1 (1) CA covers several physiological mechanisms aiming at adequate nutrient supply to the brain accord-
ing to its needs. The current Delphi consensus process focuses on the clinical assessment of the 
ability to maintain constant global CBF in response to different external stimuli
N/A N/A 95.8%
2 (1) CA impairment is not binary, but a process that results in dynamic narrowing of the CBF plateau 
between the lower and upper limit of CA and probably also in dynamic shifts in the location of the 
plateau on the CPP axis
N/A N/A 91.7%
3 (2) A CPP below 50 mmHg should never be accepted N/A N/A 83.3%
4 (2) Potential side effects of elevated CPP, such as cardiopulmonary complications and brain hyperperfu-
sion, may occur in the higher ranges of CPP. In these ranges, additional monitoring for such side 
effects may be considered
N/A N/A 100%
5 (2) Both intensity and duration of low CPP insults are determinant in terms of association with poor 
outcome
83.3% 85.7%
6 (2) Both intensity and duration of high CPP insults are determinant in terms of association with poor 
outcome
83.3% 85.7%
7 (2) Episodes of low CPP are more detrimental than episodes of high CPP 70.8% 85.7%
8 (2) Because of potential dynamic CA impairment, absolute and universal CPP targets do not exist. The safe 
CPP zone can differ between individuals and can change within individuals
100% 100%
9 (2) The CPP target zone depends on CA status as well as on other variables, and is/can be narrower than 
the area between the lower and upper limit of CA
78.3% 100%
10 (4) The correlation between extracellular glutamate concentration as measured with microdialysis and 
CPP is inaccurate in reflecting CA
77.8% 85.7%
11 (4) The correlation between extracellular glutamate concentration as measured with microdialysis and 
CPP is not validated as a reflection of CA
76.5% 93.7%
12 (4) Current methods to estimate CA status are insufficiently understood. The different indices produce 
different information
73.9% 95.2%
13 (4) Information on CA status may be helpful, but is subordinate to ICP, CPP and PbO2 signals 78.3% 81.0%
14 (5) Impaired CA worsens tolerability for high ICP (i.e., association with worse outcome occurs at lower ICP 
values)
69.6% 90.5%
15 (5) Impaired CA worsens tolerability for low PbO2 (i.e., association with worse outcome occurs at higher 
PbO2 values)
59.1% 85.0%
16 (5) Impaired CA worsens overall tolerability for secondary insults (i.e., unfavorably shifts the thresholds 
associated with worse outcome)
87.0% 95.2%
17 (5) Whether overall CA status is intact or deficient, has an independent association with outcome (regard-
less of actual CPP)
78.3% 100%
18 (6) The priority for research on CA is high 69.6% 76.2%
19 (6) When a new CA assessment method is developed, it should be validated against a method that 
includes quantitative CBF analysis in the equation, either in animal research in the lab or in patients
N/A N/A 91.7%
20 (6) CA research should move to patient studies, investigating whether CA-based protocols are safe and 
whether they lead to different treatment strategies and different outcomes
N/A N/A 100%
21 (6) Research should focus on prospective patient feasibility studies to test protocols that incorporate CA 
information
82.6% 85.7%
22 (6) Research should focus on prospective patient feasibility studies to test whether dynamic CPP targets 
from CPPopt algorithms can be achieved/maintained
78.3% 90.5%
23 (6) Research should focus on prospective patient safety studies on the implementation of CA information 
in clinical situations
78.3% 85.7%
24 (6) Research should focus on prospective patient safety studies on dynamic CPP targets from CPPopt 
algorithms
72.7% 85.7%
25 (6) Research should focus on randomized controlled trials on dynamic CPP targets from CPPopt algo-
rithms versus standard CPP management
69.6% 81.0%
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the patient’s autoregulatory status, which may deter-
mine whether the ‘minimal optimal CPP threshold’ is 
closer to 60 or 70  mmHg (within the recommended 
60–70 mmHg range) (1). It is important to realize that 
the 60–70 mmHg range simply reflects an average safe 
zone derived from a retrospective and static perspective 
at a population level, and does not take into account the 
dynamic nature of CA status in an individual patient. 
Importantly, the detrimental consequences of second-
ary insults relate to both intensity and duration.
Section 3 deals with the implementation of informa-
tion on CA status in management protocols, which 
is strongly related to the methods of assessing CA in 
Sect.  4. Little agreement existed on the accuracy, reli-
ability and validity of the various methods that have 
been developed to measure CA status. The question 
on validity formed a central part of this discussion, 
especially given the absence of a gold standard to vali-
date against. In particular, the correlation indices are 
based on strictly mathematical and linear interpreta-
tions of pressure reactivity. It was felt that validation 
of any method against patient outcome is highly rel-
evant, but insufficient. Ideally, continuous quantita-
tive CBF data should be in the numerator of any index. 
In spite of validation deficits, because PRx obtained 
higher scores than all other metrics in the question-
naires it was agreed that PRx to date can be considered 
the most accepted method to continuously monitor 
CA in patients and that patient research based on PRx 
should continue. The other correlation methods that 
have been proposed in the literature are not simply 
interchangeable with PRx. In line with the issue of CA 
measurement, there was also no agreement on how to 
safely translate CA information into clinical manage-
ment protocols. This largely reflected uncertainty due 
to insufficient evidence. Interestingly, one of the initial 
statements on which no consensus could be reached 
was, “The implementation of estimations of CA status 
in clinical decisions is still a theoretical concept.” Those 
experts who were critical of CA monitoring approaches 
agreed with this statement, whereas those experts who 
were enthusiastic about PRx-based CPPopt algorithms 
disagreed.
Section 5 focuses on the association of CA status with 
outcome. There was a large degree of agreement on the 
existence of associations between CA status, tolerability 
for and total burden of secondary insults on outcome. In 
this regard, the experts also expressed a need for com-
prehensive integration of all different multimodality 
monitoring signals, without the ability to provide signifi-
cant evidence-based advice at present. Finally, in Sect. 6 
a research agenda was discussed. Given the important 
role of CA in TBI pathophysiology acknowledged by all 
experts, but also the validation deficit of CA assessment 
methods on the other hand, research priority was consid-
ered high. Even if PRx is not the perfect monitor for CA, 
but when protocols based on it would improve outcome, 
then this can be considered valuable progress. Therefore, 
the experts took the pragmatic decision to recommend 
in parallel that (1) any new methods developed should 
be validated against a method that includes quantitative 
CBF analysis in the equation; and (2) at the same time 
clinical CA research should move on to well-designed 
prospective patient studies with a focus on safety and fea-
sibility to evaluate the computational models based on 
PRx.
Discussion
The Delphi process on the clinical assessment of the abil-
ity to maintain constant global CBF in response to dif-
ferent external stimuli in adult ventilated, sedated and 
ICP-monitored severe TBI patients resulted in 25 con-
sensus statements. Most consensus is in line with and 
supported by current evidence, e.g., the dynamic nature 
of CA impairment [21, 25, 37, 38], a lower safe thresh-
old for CPP of 50 mmHg that should not be trespassed 
Table 2 Statements of no consensus
CA cerebrovascular autoregulation
No (section) Statement of no consensus Score expressing agreement with mak-
ing a statement of no consensus (round 
3)
1 (3) There is no consensus on the manner how information on CA status should be used in 
clinical practice
100%
2 (4) There is no consensus regarding sufficient accuracy of any CA assessment method that 
can be used in clinical practice
87.5%
3 (4) There is no consensus regarding sufficient reproducibility of any CA assessment method 
used in clinical practice
87.5%
4 (4) There is no consensus regarding sufficient validity of any CA assessment method used in 
clinical practice
87.5%
5 (4) There is no consensus on the safety of implementing CA status in clinical practice 87.5%
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[39], and the importance of secondary insult duration 
as well as intensity [37, 40–43]. Evidence is emerging on 
the non-linearity and hysteresis of the CA buffer and on 
different physiological mechanisms explaining the lower 
and the upper limit of autoregulation [26, 44]. There are 
concerns whether this complexity can be detected by 
correlation indices and associated computational algo-
rithms, although these methods seem to have potential. 
Several correlation methods have been proposed to date 
that contain different physiological information [46]. 
However, the central issues dominating the discussion on 
clinical CA assessment and its bedside use concerned the 
validity of the proposed methods and the availability of 
prospective patient data.
It has become evident that while population-based 
data provide a useful guideline to care, each injured indi-
vidual has numerous factors that contribute to ultimate 
outcome. The consensus was high that understanding 
of the role of CA, its refinement and validation of meas-
urement, and implementation of CA-related treatment 
strategies in evidence-based protocols is a promising 
approach, although to date it lacks enough critical liter-
ature for widespread use. Given the validation deficit of 
current methods to assess CA, research should invest in 
the development of new methods, to be validated against 
a method that includes quantitative CBF measurement 
in the equation. This should preferably start from animal 
models in which continuous quantitative CBF is meas-
ured under varying physiological circumstances to be 
then introduced at the bedside in well-designed prospec-
tive trials [44, 45]. However, redirecting focus on valida-
tion in the lab will obviously set back clinical efforts and 
prevent attempts to build further on the valuable parts of 
previous clinical work. In this regard, PRx was consid-
ered the most studied and therefore most accepted CA 
assessment method, in spite of lack of hard validation, 
concerns that it cannot capture different behavior of CA 
with increasing versus decreasing CPP and that interfer-
ence of metabolic and oxygenation variables are insuffi-
ciently understood, poor signal to noise ratio and need 
for additional software not approved for medical use [26, 
44, 47]. Ultimately, the lack of consensus for many of our 
statements was a reflection of the lack of evidence from 
patient studies. Therefore, there was near unanimity that 
the research agenda should include prospective patient 
feasibility and safety studies to evaluate PRx and PRx-
based algorithms. We are currently eagerly awaiting the 
results of the Cogitate randomized trial on the automated 
assessment and individual implementation of a CPPopt 
algorithm in TBI patients that focuses on feasibility and 
safety, but not on resources needed. In the consensus 
statements, a deliberate distinction is made between the 
general concept of incorporation of CA information in 
clinical situations and the more specific application of 
autoregulation guided CPP (CPPopt) algorithms; both 
were considered equally important. This again reflects 
the view that research on the clinical understanding 
of CA and the development of new measurement and 
management methods should continue in parallel with 
patient studies using PRx as the currently most accepted 
CA monitoring method. The next step should then be a 
well-designed randomized controlled trial comparing 
dynamic CPP targets with standard CPP management, 
that—if successful—could alleviate the long-standing 
uncertainty as to the CPP recommendations in the adult 
TBI guidelines [1–4]. Before that, management decisions 
based on these methods should not be applied in routine 
care and outside of a clinical trial requiring consent. Fur-
ther, additional fundamental research will remain neces-
sary to improve our understanding of the complex, vast 
and fascinating field of human CBF regulation.
One limitation of the current consensus relates to 
the number of participants involved, which may reflect 
the fact that only a certain number of experts feels suf-
ficiently comfortable to make statements on CA. Since 
the controversies on this topic constituted the trigger for 
the current project, we made sure to include all different 
opinions in the group. The lack of consensus on certain 
statements, particularly in Sects. 3 and 4, confirmed that 
a broad spectrum of opinions was represented in the cur-
rent Delphi process, and thereby highlights its value.
The goal of the present Delphi process was to create 
clarity for the neuro-intensive care specialist on the use 
of CA in the management of adult severe TBI. The lack 
of validated CA assessment methods and insufficient evi-
dence from patient studies on the incorporation in man-
agement protocols preclude any specific advice on the 
use of any specific method. At the same time, all experts 
agree on the importance of CA status in TBI pathophysi-
ology. Although the CPP limits of the zone of constant 
CBF may shift, there was consensus that CPP should 
not drop below 50  mmHg. The monitoring of ABP and 
ICP is fundamental in these patients, and the monitor-
ing of PbO2 can help to detect insults of inadequate CPP 
in an individual, despite CPP being above the ‘generic’ 
50  mmHg threshold. Also, it is important to regularly 
review trends of ICP and CPP signals over several hours, 
which may provide a rough estimation of CA status. 
At most, this information may help to reduce ICP by 
increasing CPP in case of intact CA, not to steer CPP into 
the zone of active CA. In this context, the Seattle Inter-
national Severe Traumatic Brain Injury Consensus Con-
ference (SIBICC) algorithms include an ABP challenge 
in tier 2 for managing high ICP, in which it is proposed 
to titrate a vasopressor or inotrope to increase ABP by 
10 mmHg for no more than 20 min [3, 4]. This simplified 
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method of testing CA is based on a challenge study in 20 
TBI patients equipped with multimodality monitoring 
by Rosenthal et al. [48]. It is important to emphasize that 
consensus was reached on the statement that informa-
tion on CA status may be helpful in TBI management, 
but that it is subordinate to ICP, CPP and PbO2 signals. 
There was unanimity that, in clinical practice, a target 
for CPP will not only depend on CA assessment, but also 
on other neuromonitoring information. In practice, this 
means that proven and validated relationships should, for 
the moment, continue to have priority over CA status.
Conclusion
Consensus amongst experts was achieved on the impor-
tance of CA status in adult severe TBI pathophysiology, 
the dynamic non-binary nature of CA impairment, its 
association with outcome and the non-existence of uni-
versal and absolute CPP targets. There was no consen-
sus on if and how to include CA information in clinical 
management protocols. In spite of validation deficits and 
its inherent limitations, it was agreed that at present, 
PRx is the most accepted method to be incorporated 
into prospective patient safety and feasibility studies on 
the integration of CA information into TBI management 
protocols.
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